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Background: Epidemiological studies have shown a strong link between human papilloma virus (HPV) infection and 
the development of cervical cancer. Certain Human Leucocyte Antigen (HLA) alleles may influence the susceptibility 
and outcome of HPV infection in carriers of those alleles. It is therefore important to investigate any potential 
protective and/or risk association between HLA and cervical neoplasia.  
Objective: To describe the risk association between HLA and cervical neoplasia in Kenyan women. 
Setting: Tigoni, Kiambu in Central Kenya. 
Method: Nested case-control study in a cervical cancer screening study. DNA was extracted from blood buffy coat 
cells. HLA typing was done by PCR to determine Class I and II gene frequencies. 
Results: In sixty six women (43 cases, 23 controls) aged 25-60 years (mean 36.98 (SD + 8.7), HLA class I B35 allele 
increased risk for cervical neoplasia, odds ratio (OR) 11.5 (95% CI 1.32-99.46). Individuals with HLA class II allele 
DR1 were 4 times more likely than controls to have a lesion OR=3.7 (95% CI 1.01-13.65) while HLA class I allele B35 
increased by 22 times the risk of LSIL OR=22.5 (95% CI 2.30-219.89); HLA class I CW7 allele was protective , OR=0.1 
(95% CI 0.003-0.72).  HLA class I B7 allele increased by 5 times the likelihood of a lesion OR=5.2 (95% CI 10.6-25.13). 
HLA class II alleles DR1 and DQ5 increased risk for HSIL, OR 6.4 (95% CI 1.53-26.89) and 3.4 (95% CI 1.02-11.81) 
respectively. HLA class I BW6 appeared protective, OR 0.2 (95% CI 0.04-095).   
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1. Introduction 
Cervical cancer is the second most common cause of 
cancer mortality among women worldwide (Franco et 
al, 2003). Epidemiological studies have shown a strong 
link between human papilloma virus (HPV) infection 
and the development of cervical cancer (Franco et al, 
1999; Walboomers et al, 1999; Baseman et al, 2005). 
HPV type 16 and 18 are responsible for over 70% of all 
cervical cancers. Although HPV infection is considered 
to be necessary or a major risk factor, it is not sufficient 
for the development of cervical cancer. Other risk 
factors such as host genetic background, and 
environmental factors may also contribute to the 
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carcinogenic process (Chan et al, 2005). Most HPV 
infections are transient and regress spontaneously and 
only a minority of women develops persistent infection 
that with time may evolve into cervical intraepithelial 
neoplasia and/or progress to invasive cervical cancer 
(Villa, 1997; Franco et al, 1999). 
Given that host immune response to HPV is thought to 
be an important determinant of HPV acquisition and 
progression to high-grade cervical lesions and cancer, it 
is plausible that human leucocyte antigen (HLA) 
variations may affect pathogenesis of cervical neoplasia 
(Beskow et al, 2005; Clerici et al, 1997; Hildesheim et al, 
1997). The major histocompatibility complex is a highly 
polymorphic gene cluster on the short arm of 
chromosome six. The genes in this cluster are divided 
into three classes with different roles in immune 
responses. HLA gene polymorphisms result in 
variations in peptide-binding cleft, therefore influencing 
the antigens bound and presented to T cells (Beskow et 
al, 2005; Wang e al, 2005). The HLA class I genes (HLA-
A, -B, and –C) present foreign antigens to CD8+ 
Cytotoxic T lymphocytes, while class II genes (HLA-DR, -
DQ and –DP) present antigenic peptides to CD4+ T 
helper cells and are important in host immune 
responses to viruses and other pathogens (Wang et al, 
2001).  
 
Figure 1: HLA typing by PCR-SSP showing gel lanes 
 
It has been shown that certain HLA class II alleles 
increase the risk for cervical carcinoma, primarily 
because the carriers of those alleles are rendered more 
susceptible to HPV type 16, the most common type of 
HPV found in cervical carcinomas. A plausible 
hypothesis is that HLA is involved in the cellular 
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immunity against HPV and that certain HLA alleles 
make carriers more susceptible to HPV infections and 
less efficient in viral clearance. A meta-analysis has 
demonstrated a protective effect of some alleles and 
haplotypes, specifically DRB1*1301 and DQB1*0603 
against development of cervical carcinoma in 18 out of 
19 studies (Beskow et al, 2005). This consistently 
strong association indicates that it would be important 
to test the protective effect and the risk of HLA class II 
haplotypes on HPV viral load for some of the most 
frequent HR-HPV types.  
The host immune system is critical in controlling HPV 
infection and determining disease outcome. HLA plays 
an important role in regulating cell-mediated immunity 
against pathogens. Because HLA class I and class II 
molecules are highly polymorphic, individuals 
expressing different alleles may differ in their ability to 
handle a given set of HPV-derived peptides, and hence 
HLA alleles may influence the outcome of persistence 
infection (Chan et al, 2005).  
The aim of this study was to describe the risk 
association between HLA and cervical neoplasia in 
group of Kenyan women.  
 
Table 1: Overall age distribution of the study 
population 
Age 
range 
Frequency Percent 
Cumulative 
percent 
25-29 14 21.2 21.2 
30-34 14 21.2 42.4 
35-39 16 24.2 66.7 
40-44 12 18.2 84.8 
45-49 5 7.6 92.4 
50+ 5 7.6 100.0 
Total 66 100.0 100.0 
 
2. Methods 
2.1 Study population 
This was a case-control study of a subset of women who 
had been screened for cervical neoplasia and HIV in 
Tigoni, Limuru Division of Kiambu District in Central 
Kenya. Initially, all women aged 25 to 60 years who 
were eligible for cervical screening were invited. A 
subset of these women who had an abnormal smear 
was randomly selected and each case had an age-
matched pap smear negative control. A purposive 
sample size of 100 (2 for 1) was recruited, but only 66 
(46 cases and 23 controls had all results for analysis. 
2.2 Grading of cervical lesions  
All women had previously been screened for cervical 
cancer by pap smears, and those who had a cervical 
lesion were graded as negative for intraepithelial 
neoplasia (normal), Low grade squamous intraepithelial 
neoplasia (LSIL), and High grade intraepithelial 
neoplasia (HSIL). Those who had a pap smear reported 
as Atypical squamous cells of undetermined significance 
(ASCUS) were re-classified as normal or LSIL after 
colposcopy and biopsy.  
2.3 HLA Typing 
For HLA typing, DNA was extracted from buffy coat cells 
by an automated DNA extraction QiagenTM EZI DSP DNA 
blood system to yield highly pure DNA. The HLA class I 
and class II typing profiles were determined by PCR-SSP 
(sequence-specific primer) with single-stranded 
oligonucleotide primers (SSOPs) method followed by 
amplification and gel electrophoresis. Interpretation 
was done on gel photography to determine the positive 
lanes and match with specific PCR products in the lot-
specific Interpretation and Specificity Tables in order to 
obtain the HLA typing of the sample DNA (Figure 1) 
(Olerup et al, 1991; Olerup et al, 1992. 
This work was done in the Kenya AIDS Vaccine 
Initiative (KAVI) laboratory in the Department of 
Medical Microbiology, University of Nairobi. 
2.4 Data and statistical analysis 
HLA class I and II phenotype frequencies were 
determined by direct counting. Subgroup analyses were 
done according to the grade of cervical lesion. Class I 
and class II gene frequencies were calculated and 
statistical differences between cases and controls 
evaluated by use of χ2 test and Fisher’s exact test as 
appropriate, for significance (Bland et al, 1995). The 
magnitude of the statistical significance of association 
was determined by means of odds ratios (ORs) and 95% 
confidence intervals (CIs). A p-value of <0.05 was 
considered significant. 
2.5 Ethical considerations 
Ethical approval to carry out this study was granted by 
the Kenyatta National Hospital/University of Nairobi 
Ethics and Research Committee (KNH/UON-ERC Study 
approval No: P7144/12/2003). 
Blood samples for HLA typing were obtained after they 
provided written, informed consent. The participants 
were also informed that they would not receive 
individual HLA typing results since, at the time, the 
results had no clinical utility.  
 
Table 2: Cervical lesions results in the study population 
Cervical 
abnormality 
Number 
(N=43) 
Percent (%) 
ASC-US 16 24.2 
ASC-H 6 6.1 
LSIL 10 15.2 
HSIL 11 16.7 
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3. Results 
A total of 66 women were enrolled for this case-control 
study (43 cases, 23 controls).  The ages ranged from 25 
to 60 years with a mean age of 36.98 (SD + 8.71 years).  
The age range frequencies are shown in Table 1.  
A total of forty three (43) or 62.2% of women had a 
cervical abnormality by pap smear or cervical biopsy 
(Table 2), of whom 24.2% had atypical squamous cells 
of undetermined significance (ASCUS), 6.1% had 
atypical squamous cell – cannot exclude a high grade 
lesion (ASC-H), 15.2% had a low grade squamous 
intraepithelial lesion (LSIL), and 16.7% had a high 
grade squamous intraepithelial lesion (HSIL). A total of 
37.8% had normal smears. For analysis, only biopsy 
confirmed cervical neoplastic lesions were considered, 
and grouped into LSIL and HSIL.  
Table 3 shows selected HLA class I and II alleles that 
were associated with increased risk for cervical 
neoplasia. The HLA class I B35 allele was associated 
with increased risk for cervical neoplasia (LSIL or HSIL) 
with an OR of 11.5 (95% CI 1.32-99.46) compared to 
controls. In addition, individuals who had HLA class II 
allele DR1 were almost 4 times more likely than 
controls to have a cervical neoplastic lesion (LSIL, 
HSIL), OR of 3.7 (95% CI 1.01-13.65).  
When only LSIL alone was considered (Table 4), HLA 
class I allele B35 was associated with increased risk, 
OR=22.5 (95% CI 2.30-219.89) and HLA class I CW7 
allele was associated with a protective role, OR=0.1 
(95% CI 0.003-0.72)  
When the risk of having HSIL alone was considered, 
those with HLA class I B7 allele appeared to be about 5 
times more likely than controls to have a cervical lesion 
OR=5.2 (95% CI 10.6-25.13); similarly HLA class II 
alleles DR1 and DQ5 also appeared to increase the risk 
for HSIL with ORs of 6.4 (95% CI 1.53-26.89) and 3.4 
(95% CI 1.02-11.81) respectively. The HLA class I BW6 
appeared to play a protective role with OR of 0.2 (95% 
CI 0.04-095) (Table 5).  
The full list of HLA allele frequencies for cases and 
controls as well as the corresponding odds ratios, 
confidence intervals and p-values can be found in the 
Supporting Information (available online at 
http://www.uonbi.ac.ke/journals/kesobap/). 
 
Table 3: Risk association between HLA alleles and cervical neoplasia 
Alleles Cervical neoplasia (LSIL, HSIL) Control O.R (95%CI) P value 
HLA class I     
B35 7 (24.1%) 1 (2.7%) 11.5 (1.32-99.46) 0.018 
BW6 21 (72.4%) 34 (91.9%) 0.2 (0.06-0.97) 0.048 
CW7 7 (24.1%) 21 (56.8%) 0.2 (0.08-0.71) 0.012 
HLA class II     
DR1 9 (31%) 4 (10.8%) 3.7 (1.01-13.65) 0.040 
 
Table 4: Risk association between HLA alleles and LSIL 
 
Alleles LSIL Control O.R (95%CI) P value 
HLA class I     
B35 5 (38.5%) 1 (2.7%) 22.5 (2.30-219.89) 0.030 
CW7 2 (15.4%) 21 (56.8%) 0.1 (0.03-0.72) 0.012 
 
 
Table 5: Risk association between HLA alleles and HSIL 
 
Alleles HSIL Control O.R (95%CI) P value 
HLA class I     
B7 5 (31.3%) 3 (8.1%) 5.2 (10.6-25.13) 0.045 
BW6 11 (68.8%) 34 (91.9%) 0.2 (0.04-0.95) 0.045 
HLA class II     
DR1 7 (43.8%) 4 (10.8%) 6.4 (1.53-26.89) 0.011 
DQ5 10 (62.5%) 12 (32.4%) 3.4 (1.02-11.81) 0.041 
 
 4. Discussion 
In the past most research on the association between 
HLA and cervical neoplasia has evaluated class II alleles 
in different populations such as American-white and -
Indian women, Caucasian women in Europe, non-
Hispanic white, Hispanic white, African-American, 
Brazilian, Japanese, (Zoodsma et al, 2005), and Chinese 
women (Chan et al, 2007), and only one in African 
women in Senegal (Lin et al, 2001). The importance of 
HLA class I antigens in cervical neoplasia is well-
established (Wang et al, 2002). Although Koehler et al 
(2010) have described HLA class I genotyping in some 
populations in the East African region, to our 
knowledge this study is the first to assess the risk 
association between HLA class I and II alleles and 
cervical neoplasia in women in the region.  
This study demonstrated that both HLA class I and II 
alleles increase the risk for cervical neoplasia of any 
grade among a group of Kenyan women. The HLA class I 
allele B35 increased the risk for any grade of cervical 
neoplasia by up to eleven times, and by twenty-two 
times for LSIL. This strong association between a HLA 
class I allele and cervical neoplasia has not been 
demonstrated before. Wang et al (2002) demonstrated 
a decreased risk for cervical cancer, HSIL or LSIL for 
women with the haplotypes HLA-CW*0202 allele across 
two ethnic groups in the US and Costa Rica, although 
according to their study, some women with cervical 
cancer also had the same allele, suggesting that the role 
of HLA molecules is only one of many factors in disease 
development. 
Our results show that the HLA class II allele DR1 was 
significantly associated with cervical neoplasia of any 
grade with odds of up to four times; other studies have 
shown that the presence of a single allele (DRB1*1301) 
(Wang et al, 2001) was associated with risk reduction 
while multiple haplotypes DRB1*1301/DQB1*0302 had 
protective association (Zoodsma et a,l 2005; Sastre-
Garau et al, 1996; Hildesheim et al, 1998). However, 4-
digit haplotyping was not done for this study therefore 
comparison with haplotypes in other studies cannot be 
made.  As in other studies (Wang et al, 2001), our 
results confirm the risk reduction as well as risk 
increase with multiple alleles.  
Wang et al (2002) separated as well as merged analysis 
for two distinct ethnic groups in the US and Costa Rica 
involving a 24,000-women cohort in Portland, Oregon, 
and 10,077 women in Guanacaste, Costa Rica. They 
observed that the extreme polymorphisms of both class 
I and II alleles are fairly evenly distributed, making 
single allele-disease associations difficult to observe.  
Different populations have different genetic pools that 
can also be influenced by ethnicity (Wang et al, 2002). 
Koehler et al (2010) indicates that there is very low 
representation of the East African population in global 
HLA databases, and given that the HLA genes are the 
most diverse of human genes, comparisons and 
inferences with gene frequencies and variants with 
disease associations are somewhat limited. However, 
with availability of high-through-put high-resolution 
HLA typing methods such as PCR-SSP that can provide 
HLA typing information with the needed level of 
molecular detail in a timely and cost-effective fashion, 
conduction of large epidemiological studies is now 
possible. Future studies should probably include the 
complete haplotypes analyses for HLA class I and II 
alleles, assessment of HPV type specificity in order to 
identify protective or risk alleles specific to oncogenic 
HPV types in disparate genetic pools in Kenya as exist in 
different ethnic groups.  The limitations in this study 
included the small numbers which reduced the power 
to make generalizable conclusions as well as the 
potential for confounding by ethnicity in a merged 
analysis. 
Efforts to develop vaccines and improved treatments 
for major diseases such as cervical cancer are hindered 
by our poor understanding of the molecular events and 
cellular mechanisms that determine clinical outcome. 
Genetic epidemiology provides a potentially powerful 
tool that may identify hitherto unknown mechanisms 
and improve our understanding of critical events in the 
evolution of disease. High throughput genotyping 
technology is projected to make it feasible to screen for 
genetic factors that determine susceptibility to 
infections such as HPV and help identify critical 
pathways of host defense and therefore generate novel 
strategies for disease prevention (Kwiatkowski, 2000). 
 
5.0 Conclusion 
This study has demonstrated that both HLA class I and 
II alleles increase the risk for cervical neoplasia of any 
grade among a group of Kenyan women. The strong 
association between a HLA class I allele and cervical 
neoplasia has not been demonstrated before. Future 
studies should include the complete haplotypes as well 
as 4-digit haplotypes analyses for HLA class I and II 
alleles, and assessment of HPV type specificity in order 
to identify protective or risk alleles specific to 
oncogenic HPV types in disparate genetic pools in 
Kenya as they exist in different ethnic groups.  The 
study limitations in this study included the small 
numbers which reduced the power to make 
generalizable conclusions as well as the potential for 
confounding by ethnicity in a merged analysis. 
However, it was an important methodological 
advancement for a local Kenyan research laboratory to 
be able to perform HLA typing. 
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